Results 11 to 20 of about 112,964 (206)
Cancer Medicine, 2019 Objective Cisplatin is the first‐line chemotherapy for ovarian cancer. However, cisplatin resistance is severely affecting the treatment efficacy. FOXO3a has been reported to be involved in reversing chemotherapy resistance.
Lili Zhao +8 more
doaj +2 more sources
Understanding cisplatin resistance using cellular models [PDF]
, 2007 Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, M +6 more
core +4 more sources
Cisplatin Resistance and Metabolism: Simplification of Complexity
CancersCisplatin is one of the most well-known anti-cancer drugs and has demonstrated efficacy against numerous tumor types for many decades. However, a key challenge with cisplatin, as with any chemotherapeutic agent, is the development of resistance with a resultant loss of efficacy.
Nikolay V. Pervushin +4 more
openaire +3 more sources
Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance
Cell Death and Disease, 2022 Hypoxia-induced cisplatin resistance is a major challenge during non-small cell lung cancer (NSCLC) treatment. Based on previous studies, we further explored the effect of eukaryotic initiation factor 5A2 (eIF5A2) in hypoxia-induced cisplatin resistance.
Guodong Xu +13 more
doaj +1 more source
Molecular mechanisms of cisplatin resistance [PDF]
Oncogene, 2011 Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.
L, Galluzzi +7 more
openaire +2 more sources
PeerJ, 2021 Backgrounds Cancer cell resistance to chemotherapy drugs such as Gemcitabine, Oxaliplatin, Cisplatin, Doxorubicin, and 5-fluorouracil account for the main reason of chemotherapy failure for HCC patients, especially for those with advanced HCC or metastasis patients.
Tang, Zuxiong +5 more
openaire +4 more sources
Pulling a MAST1 on Cisplatin Resistance [PDF]
Cancer Cell, 2018 In this issue of Cancer Cell, Jin and colleagues use a kinome-wide screen to identify MAST1 as a cause of cisplatin resistance. They demonstrate that this kinase is a novel activator of MEK1 and the MAPK cascade and that it can harness pathway output to block cisplatin-induced cell death.
Ankita B, Jaykumar +2 more
openaire +2 more sources
Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. [PDF]
PLoS ONE, 2014 Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy. Even when cisplatin treatment is successful the patient is often left with a residual teratoma at
Paolo B Abada, Stephen B Howell
doaj +1 more source
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review [PDF]
, 2007 Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
Pavlakis, Nick +5 more
core +1 more source
Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]
, 2009 Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
Pavlakis, Nick +5 more
core +1 more source